Insight Molecular Diagnostics Inc. (IMDX): who owns it and who trades it
As of Nov 16, 2026, IMDX insiders reported 7 purchases worth $5.7M in the last 12 months. The largest buyer was Neal C Bradsher (10% owner), with $3M. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Insight Molecular Diagnostics
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IMDX
40 funds and institutions reported IMDX shares worth $109M at the end of Q2 2026, about 57% of the company. The largest holder is Broadwood Capital Inc with 39.4%.
Funds and institutions (13F) 57%Everyone else 43%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Broadwood Capital Inc | 12.68M | 39.43% | $74.8M | +6% |
| AWM Investment Company, Inc. | 2.84M | 8.82% | $16.7M | +1% |
| Vanguard Capital Management LLC | 735,847 | 2.29% | $4.3M | +37% |
| Pura Vida Investments, LLC | 484,845 | 1.51% | $2.9M | -49% |
| Family Office Research LLC | 368,849 | 1.15% | $2.2M | +190% |
| Geode Capital Management, LLC | 256,903 | 0.80% | $1.5M | -2% |
| FNY Investment Advisers, LLC | 182,561 | 0.57% | $1.1M | -26% |
| Jane Street Group, LLC | 157,682 | 0.49% | $930K | New |
| BlackRock, Inc. | 150,521 | 0.47% | $888K | +11% |
| Vanguard Fiduciary Trust Co | 124,576 | 0.39% | $735K | -6% |
| State Street Corp | 92,124 | 0.29% | $544K | +82% |
| Millennium Management LLC | 82,499 | 0.26% | $487K | -20% |
| UBS Group AG | 53,276 | 0.17% | $314K | +134% |
| Northern Trust Corp | 49,090 | 0.15% | $290K | No change |
| Osaic Holdings, Inc. | 39,136 | 0.12% | $231K | +62% |
| Morgan Stanley | 35,515 | 0.11% | $210K | -2% |
| Jefferies Financial Group Inc. | 18,100 | 0.06% | $107K | New |
| Marshall Wace, LLP | 16,597 | 0.05% | $97.9K | New |
| ExodusPoint Capital Management, LP | 14,029 | 0.04% | $82.8K | New |
| Axq Capital, LP | 13,407 | 0.04% | $79.1K | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IMDX insiders reported $5.7M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Broadwood Partners, L.P. +2 | 10% owner | Purchase | 250,923 | $3.64 | $913K | Form 4 |
| Apr 24, 2026 | Broadwood Partners, L.P. +2 | 10% owner | Purchase | 38,880 | $3.53 | $137K | Form 4 |
| Apr 23, 2026 | Broadwood Partners, L.P. +2 | 10% owner | Purchase | 280,381 | $3.50 | $981K | Form 4 |
| Apr 20, 2026 | Broadwood Capital Inc +2 | 10% owner | Purchase | 40,690 | $3.88 | $158K | Form 4 |
| Apr 17, 2026 | Broadwood Capital Inc +2 | 10% owner | Purchase | 40,114 | $3.57 | $143K | Form 4 |
| Apr 16, 2026 | Broadwood Capital Inc +2 | 10% owner | Purchase | 102,057 | $3.45 | $352K | Form 4 |
| Feb 10, 2026 | Neal C Bradsher +2 | 10% owner | Purchase | 521,739 | $5.75 | $3M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Neal C Bradsher | 10% owner | $3M | – | Feb 10, 2026 |
| Broadwood Partners, L.P. | 10% owner | $2M | – | Apr 27, 2026 |
| Broadwood Capital Inc | 10% owner | $653K | – | Apr 20, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IMDX short interest
Low short interest. 3.1% of IMDX shares are sold short: about 1 share in 32. Over the last 12 reports the number of shares short went down 13%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.03M IMDX shares were sold short, 3.1% of the shares outstanding, up 8.0% from the report before. At the average daily volume of 202,771 shares, buying them all back would take about 5.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.03M | 3.13% | +8% | 202,771 | 5.1 |
| Oct 15, 2026 | 949,512 | 2.90% | -2% | 292,353 | 3.2 |
| Sep 30, 2026 | 973,029 | 2.97% | -2% | 334,261 | 2.9 |
| Sep 15, 2026 | 992,474 | 3.03% | +7% | 208,575 | 4.8 |
| Aug 31, 2026 | 930,741 | 2.84% | -15% | 105,676 | 8.8 |
| Aug 14, 2026 | 1.09M | 3.33% | +1% | 309,492 | 3.5 |
| Jul 31, 2026 | 1.07M | 3.34% | -14% | 96,353 | 11.1 |
| Jul 15, 2026 | 1.25M | 3.87% | +24% | 287,089 | 4.3 |
| Jun 30, 2026 | 1.01M | 3.13% | -12% | 234,444 | 4.3 |
| Jun 15, 2026 | 1.15M | 3.56% | -10% | 262,441 | 4.4 |
| May 29, 2026 | 1.28M | 3.98% | +8% | 318,377 | 4.0 |
| May 15, 2026 | 1.18M | 3.68% | +66% | 561,599 | 2.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Insight Molecular Diagnostics company events
Insight Molecular Diagnostics filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Sep 21, 2026.
- Sep 21, 2026AgreementAs previously reported, Insight Molecular Diagnostics Inc. entered into an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the “Merger Agreement”), by and among the Company, CNI Monitor Sub… Filing
- Aug 10, 2026AnnouncementThe information provided in “Item 7.01 - Regulation FD Disclosure” of this Current Report on Form 8-K is incorporated by reference into this Item 8.01. Filing
- Jun 17, 2026LeadershipAs reported below under Item 5.07 of this report, Insight Molecular Diagnostics Inc. held its 2026 Annual Meeting of Shareholders on June 11, 2026, at which the Company’s shareholders approved an amendment to the Company’s Amended and Restated 2018 Equity Incentive Plan (as previously amended, the… Filing
- May 13, 2026ResultsReleased financial results. Filing
- May 13, 2026AnnouncementAmended an earlier report. IMDx announced that it had entered into a Specimen Collection Agreement with Quest Diagnostics for certain specimen collection-related services related to the Company’s GraftAssureCore TM test, a blood test designed to measure donor-derived cell free DNA (dd-cfDNA) using a novel PCR-based… Filing
- Apr 30, 2026AnnouncementInsight Molecular Diagnostics Inc. filed its Annual Report on Form 10-K for the year ended December 31, 2025, which incorporated by reference the Company’s Third Amended and Restated Bylaws (as amended and restated, the “Bylaws”) as Exhibit 3.5. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Feb 26, 2026AgreementInsight Molecular Diagnostics Inc. entered into a Specimen Collection Agreement with Quest Diagnostics Incorporated. Filing
- Feb 12, 2026AgreementInsight Molecular Diagnostics Inc. entered into securities purchase agreements with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,482,498 shares of the Company’s common stock, no par value per share, and (ii) Pre-Funded Warrants to purchase up to… Filing
- Feb 11, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Insight Molecular Diagnostics financials
Famous investors that hold IMDX
1 of the 50 well-known investors we track reported holding IMDX in their latest 13F filing. The largest position is Ken Griffin's, worth $120K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 33,511 | $120K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Insight Molecular Diagnostics Inc. (IMDX) stock
Who owns the most IMDX stock?
The largest reported owner of Insight Molecular Diagnostics Inc. (IMDX) is Broadwood Capital Inc, with 39.4% of the company. In total, 40 funds and institutions reported holding IMDX at the end of Q2 2026, together about 57% of the shares. See the largest owners.
Are IMDX insiders buying or selling?
In the last 12 months, IMDX insiders reported 7 open-market purchases worth $5.7M and no sales. The latest trade was on Apr 27, 2026. See every trade.
What is the short interest in IMDX?
As of Oct 30, 2026, 1.03M IMDX shares were sold short, 3.1% of the shares outstanding, up 8.0% from the report before. At the average daily volume of 202,771 shares, buying them all back would take about 5.1 trading days (days to cover). See the history.
Which famous investors hold IMDX?
1 of the 50 well-known investors we track reported IMDX in their latest 13F filing, including Ken Griffin. The largest position is worth $120K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.